You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 25, 2025

Details for Patent: 10,093,697


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,093,697 protect, and when does it expire?

Patent 10,093,697 protects BYLVAY and is included in one NDA.

This patent has sixty-four patent family members in thirty-one countries.

Summary for Patent: 10,093,697
Title:IBAT inhibitors for the treatment of liver diseases
Abstract: The present invention regards specific IBAT inhibitors useful in the prophylaxis and/or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions.
Inventor(s): Gillberg; Per-Goran (Molndal, SE), Graffner; Hans (Helsingborg, SE), Starke; Ingemar (Gothenburg, SE)
Assignee: Albireo AB (N/A)
Application Number:15/726,203
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 10,093,697: A Comprehensive Guide

Introduction

Understanding the scope and claims of a patent is crucial for inventors, researchers, and businesses to navigate the complex landscape of intellectual property. This article will delve into the specifics of United States Patent 10,093,697, focusing on its claims, scope, and the broader patent landscape.

Overview of the Patent

United States Patent 10,093,697, titled "IBAT inhibitors for the treatment of liver diseases," pertains to specific inhibitors of the ileal bile acid transporter (IBAT) and their application in the prophylaxis and treatment of liver diseases[4].

Claims of the Patent

The claims section of a patent is critical as it defines the scope of the invention and what is protected by the patent.

Independent Claims

Independent claims are the broadest claims in a patent and define the core invention. For US Patent 10,093,697, the independent claims typically include the composition of the IBAT inhibitors, their chemical structures, and the methods for their use in treating liver diseases.

Dependent Claims

Dependent claims narrow down the scope of the independent claims by adding additional limitations. These claims often specify particular aspects of the invention, such as specific compounds, dosages, or methods of administration.

Claim Structure

The claim structure includes both composition-of-matter claims (e.g., the chemical compounds themselves) and method-of-use claims (e.g., how these compounds are used to treat liver diseases). This dual approach ensures comprehensive protection for the invention.

Scope of the Patent

The scope of a patent is determined by its claims and is a critical factor in determining what is protected and what is not.

Chemical Compounds

The patent covers specific chemical compounds that act as IBAT inhibitors. These compounds are detailed in the claims and include their structural formulas and chemical names. For example, the patent mentions compounds like "(2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid"[4].

Methods of Use

The patent also covers the methods for using these IBAT inhibitors in the treatment of liver diseases. This includes the administration routes, dosages, and any specific treatment protocols.

Patent Landscape

Understanding the broader patent landscape is essential for identifying potential competitors, collaborators, and areas for further innovation.

Prior Art

Prior art refers to existing patents and publications that are relevant to the current patent. The prior art section of US Patent 10,093,697 lists previous patents and publications related to IBAT inhibitors and liver disease treatments. This helps in understanding how the current patent differs from and builds upon existing knowledge[4].

Global Patent Family

To fully understand the scope of protection, it is important to look at the global patent family. This involves searching international patent databases such as those provided by the European Patent Office (EPO), Japan Patent Office (JPO), and the World Intellectual Property Organization (WIPO)[1].

Competitors and Collaborators

Identifying other patents and patent holders in the same field can reveal potential competitors and collaborators. This can be done by searching patent databases and analyzing the patent portfolios of other companies and researchers working on similar technologies.

Legal and Regulatory Considerations

Presumption of Validity

Under U.S. law, a patent is presumed valid unless proven otherwise. This means that any challenges to the patent must overcome this presumption[5].

Defenses

Defenses against patent infringement claims can include arguments that the patent is invalid or that the accused product or process does not infringe the claims of the patent.

Conducting a Comprehensive Patent Search

To fully analyze the scope and claims of US Patent 10,093,697, one must conduct a comprehensive patent search.

Using USPTO Resources

The United States Patent and Trademark Office (USPTO) provides several tools for patent searching, including the Patent Public Search tool, Global Dossier, and the Patent and Trademark Resource Centers (PTRCs)[1].

International Searches

Searching international patent databases is crucial to understand the global patent landscape. Resources like the European Patent Office's esp@cenet and the World Intellectual Property Organization's PATENTSCOPE can be invaluable[1].

Data and Statistics

Patent Claims Research Dataset

The USPTO's Patent Claims Research Dataset can provide insights into patent scope and claims trends. This dataset includes detailed information on claims from U.S. patents granted between 1976 and 2014 and U.S. patent applications published between 2001 and 2014[3].

Economic Impact

Understanding the economic impact of patents in the pharmaceutical sector can also provide context. Studies by the USPTO's Office of the Chief Economist can offer insights into the economic benefits and challenges associated with patent protection in this field[3].

Key Takeaways

  • Claims Analysis: The claims of US Patent 10,093,697 define the specific IBAT inhibitors and their methods of use, providing a clear understanding of what is protected.
  • Scope of Protection: The scope includes both the chemical compounds and the methods for their use in treating liver diseases.
  • Patent Landscape: Understanding the global patent family and prior art is crucial for navigating the competitive landscape.
  • Legal Considerations: The patent is presumed valid, and any challenges must overcome this presumption.
  • Comprehensive Search: Using USPTO resources and international databases is essential for a thorough analysis.

FAQs

Q: What is the main subject of US Patent 10,093,697?

A: The main subject is IBAT inhibitors for the treatment of liver diseases.

Q: How do I determine the scope of protection for this patent?

A: The scope is determined by the claims, which include specific chemical compounds and methods of use.

Q: Where can I find more information on the global patent family for this invention?

A: You can use resources like the Global Dossier and international patent databases such as those provided by the EPO and WIPO.

Q: What is the significance of the presumption of validity in patent law?

A: It means that a patent is assumed to be valid unless proven otherwise, making it harder to challenge the patent.

Q: How can I conduct a comprehensive patent search related to this invention?

A: Use USPTO resources like the Patent Public Search tool and international databases, and consult with Patent and Trademark Resource Centers (PTRCs) if necessary.

Sources

  1. USPTO: Search for patents - USPTO. [Online]. Available: https://www.uspto.gov/patents/search
  2. ACUS: U.S. Patent Small Claims Court. [Online]. Available: https://www.acus.gov/research-projects/us-patent-small-claims-court
  3. USPTO: Patent Claims Research Dataset - USPTO. [Online]. Available: https://www.uspto.gov/ip-policy/economic-research/research-datasets/patent-claims-research-dataset
  4. Google Patents: US10093697B2 - IBAT inhibitors for the treatment of liver diseases. [Online]. Available: https://patents.google.com/patent/US10093697B2/en
  5. US Code: 35 USC 282: Presumption of validity; defenses. [Online]. Available: https://uscode.house.gov/view.xhtml?req=granuleid%3AUSC-1994-title35-section282&num=0&edition=1994

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 10,093,697

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ipsen BYLVAY odevixibat CAPSULE, PELLETS;ORAL 215498-001 Jul 20, 2021 RX Yes No ⤷  Try for Free ⤷  Try for Free METHOD OF TREATING PRURITUS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC) ⤷  Try for Free
Ipsen BYLVAY odevixibat CAPSULE, PELLETS;ORAL 215498-001 Jul 20, 2021 RX Yes No ⤷  Try for Free ⤷  Try for Free METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 12 MONTHS OR OLDER SUFFERING FROM ALAGILLE SYNDROME (ALGS) ⤷  Try for Free
Ipsen BYLVAY odevixibat CAPSULE, PELLETS;ORAL 215498-001 Jul 20, 2021 RX Yes No ⤷  Try for Free ⤷  Try for Free METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC) ⤷  Try for Free
Ipsen BYLVAY odevixibat CAPSULE, PELLETS;ORAL 215498-001 Jul 20, 2021 RX Yes No ⤷  Try for Free ⤷  Try for Free METHOD OF TREATING CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OR OLDER SUFFERING FROM ALAGILLE SYNDROME (ALGS) ⤷  Try for Free
Ipsen BYLVAY odevixibat CAPSULE, PELLETS;ORAL 215498-003 Jul 20, 2021 RX Yes Yes ⤷  Try for Free ⤷  Try for Free METHOD OF TREATING PRURITUS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC) ⤷  Try for Free
Ipsen BYLVAY odevixibat CAPSULE, PELLETS;ORAL 215498-003 Jul 20, 2021 RX Yes Yes ⤷  Try for Free ⤷  Try for Free METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC) ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,093,697

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden1051165Nov 8, 2010

International Family Members for US Patent 10,093,697

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 3400944 ⤷  Try for Free PA2021012 Lithuania ⤷  Try for Free
European Patent Office 3400944 ⤷  Try for Free LUC00242 Luxembourg ⤷  Try for Free
European Patent Office 3400944 ⤷  Try for Free 301157 Netherlands ⤷  Try for Free
European Patent Office 3400944 ⤷  Try for Free CA 2022 00001 Denmark ⤷  Try for Free
European Patent Office 3400944 ⤷  Try for Free 2021C/554 Belgium ⤷  Try for Free
European Patent Office 3400944 ⤷  Try for Free 122021000075 Germany ⤷  Try for Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.